Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...
(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...
CNW/ - Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex ...
The phase 3 trial for high-risk MDS with RARA overexpression did not achieve its primary endpoint of CR rate. Tamibarotene-Vidaza treatment showed a 23.8% CR rate, not significantly different from the ...
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...
CEO, Dr Juho Jalkanen, talked with Proactive about the company’s planned €40 million rights offering and the next development ...
Azacitidine (Vidaza, Celgene) is standard treatment for patients with myelodysplastic syndrome (MDS) and will remain the treatment of choice — at least for now. A new study that tested two different ...
Hypomethylating agents (HMAs) are underutilized in high-risk MDS patients, especially among older, female, and non-White individuals. Only 16.1% of Medicare patients with newly diagnosed MDS received ...
Building on the clinical results of the BEXMAB trial, the IIT aims to evaluate bexmarilimab with an oral HMA backbone to further strengthen evidence of its efficacy in research participants with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results